Abstract: Objective To investigate the clinical effect of patients with Luminal A breast cancer treated with chemotherapy and endocrine therapy.Methods A total of 84 patients with Luminal A type breast cancer were observed in 2015 and 2017. The patients were randomly divided into control group （n=42） and observation group （n=42）. The control patients were treated with chemotherapy alone whereas those for observation were treated in combination with tamoxifen endocrine therapy. CD3⁺,CD4⁺,CD8⁺,and CD4⁺/CD8⁺cells were measured by flow cytometry pre- and post- treatment. Simultaneously,IFN-γ,TNF-α,IL-4,and IL-10 cytokines were detected. The survival time at different time points after treatments was compared for the clinical efficacy in the two groups.Results No significant difference was noted in the efficacy rate between the treatment group （64.29%） and the control （47.62%） （P>0.05）. The number of CD3⁺/CD4⁺CD8⁺ and CD4⁺/CD8⁺cells in the group of combination treatments was increased when compared with the control （P<0.05）. But the CD3⁺/CD8⁺cell counts as well as IL-10 in the combination group were lower than in the control （ P<0.05）. No significant difference,however,was found in survival rates of 1yr,3yr,and 5yr between the two groups （P>0.05）.Conclusion The combination of chemotherapy and tamoxifen endocrinotherapy in patients with Luminal A type breast cancer may help improve the immunity,inhibit inflammatory factors and prolong the survival of patients.

Key words: Chemotherapy, Endocrine therapy, Luminal A breast cancer, Flow cytometry, Inflammatory cutokines, Sunbibal